Compare Ginkgo Bioworks Holdings Inc (DNA) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Krispy Kreme Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.54 (market cap $515.15M), while Krispy Kreme Inc trades at $3.13 (market cap $544.79M). The key difference: Ginkgo Bioworks Holdings Inc and Krispy Kreme Inc are close in size by market cap, and Krispy Kreme Inc pays a 3.47% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | DNUT | |
|---|---|---|
Market Cap | $515.15M | $544.79M |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $4.70 |
52-Week Low | $5.48 | $2.92 |
Enterprise Value | $617.10M | $1.79B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Krispy Kreme (DNUT) trades at $3.34, up 3.41% today, with a bullish technical signal from oscillators and mixed earnings history. The company reported a net loss of -$515.77M in 2025 but shows margin improvement and a capital-light refranchising strategy. Recent news highlights a turnaround focus, with the CEO affirming progress on profitability and leverage reduction.
Outlook hinges on execution of the turnaround plan; opportunities include international expansion and cost controls, but risks persist from high debt and competitive pressures. Analysts are cautiously optimistic with a 50% buy rating, though negative profitability metrics warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
